Trinity Biotech (TRIB) Net Cash Flow (2021 - 2024)

Trinity Biotech has disclosed Net Cash Flow across 4 years of filings, most recently posting $2.7 million for Q4 2024.

• Net Cash Flow for Q4 2024 came in at $2.7 million, up 213.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.7 million (up 309.31% YoY), and the FY2025 annual result was $246000.0, down 85.1% from the prior year.
• Net Cash Flow came in at $2.7 million for Q4 2024 at Trinity Biotech, up from -$3.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $2.7 million in Q4 2024 to a low of -$7.1 million in Q2 2023.
• The 4-year median for Net Cash Flow is -$1.4 million (2021), against an average of -$1.7 million.
• Across the five-year window, Net Cash Flow tumbled 395718.71% in 2023 and jumped 213.0% in 2024, its largest moves.
• Trinity Biotech's Net Cash Flow stood at -$2.2 million in 2021, then soared by 67.66% to -$696000.0 in 2022, then tumbled by 237.21% to -$2.3 million in 2023, then surged by 213.0% to $2.7 million in 2024.
• The last three Net Cash Flow figures came in at $2.7 million (Q4 2024), -$3.9 million (Q2 2024), and -$3317.0 (Q1 2024), per Business Quant data.